Location
Israel, Middle East
Check Size
$500K - $3M
Investment Stage
Seed
Series A
Series B
Focus Areas
BioTech
About Investor
Ken Belotsky is Founding Partner at Negev Capital in Tel Aviv, Israel, leading seed- and Series A investments ($500 K–$3 M, sweet spot $1 M) in biotech and psychedelic drug development. His most recent deal was a $1 M Series B in Gilgamesh Pharmaceuticals. With a background as an investor-operator in life sciences, Ken drives innovation in mental health therapeutics.
Similar Investors
NP
Noah Pickholtz
Israel, Middle East
$25K - $1M
Idea
,Pre Seed
,RR
Ran Regev
Israel, Middle East
$100K - $12M
Series A
,Series B
,RG
Roy Glasberg
Israel, Middle East
$500K - $2M
Seed
,Series A
,YA
Yuval Ariav
Israel, Middle East
$500K - $3.5M
Seed
,Series A
,AF
Ariel Finkelstein
Israel, Middle East
$50K - $700K
Pre Seed
,Seed
,AS
Amy Swartz
United Arab Emirates, Middle East
$100K - $5M
Seed
,Series A
,Is this You?
Is this you? Have any edits?
Fill out our update request form and we'll update ASAP